Novel calcium sensing receptor ligands: a patent survey

Bibliography

• Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001;81:239-97
   PubMed Web of Science ®Google Scholar
• Pin JP, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 2003;98:325-54
   PubMed Web of Science ®Google Scholar
• Jingami H, Nakanishi S, Morikawa K. Structure of the metabotropic glutamate receptor. Curr Opin Neurobiol 2003;13:271-8
   PubMedGoogle Scholar
• Jingami H, Nakanishi S, Morikawa K. Structure of the metabotropic glutamate receptor. Curr Opin Neurobiol 2003;13:271-8
   PubMedGoogle Scholar
• Brown EM, Gamba G, Riccardi D, Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 1993;366:575-80
   PubMed Web of Science ®Google Scholar
• Bai M, Quinn S, Trivedi S, Expression and characterization of inactivating and activating mutations in the human Ca2+ sensing receptor. J Biol Chem 1996;271:19537-45
   PubMed Web of Science ®Google Scholar
• Chang W, Shoback D. Extracellular Ca2+ sensing receptors: an overview. Cell Calcium 2004;35:183-96
   PubMed Web of Science ®Google Scholar
• Riccardi D, Park J, Lee WS, Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci USA 1995;92:131-5
   PubMed Web of Science ®Google Scholar
• Ruat M, Molliver ME, Snowman AM, Calcium sensing receptor: molecular cloning in rat and localization to nerve terminals. Proc Natl Acad Sci USA 1995;92:3161-5
   PubMedGoogle Scholar
• Ferry S, Traiffort E, Stinnakre J, Development and adult expression of rat calcium-sensing receptor transcripts in neurons and oligodendrocytes. Eur J Neurosci 2000;12:872-84
   PubMedGoogle Scholar
• Hofer AM, Brown EM. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 2003;4:530-8
   PubMed Web of Science ®Google Scholar
• Garrett JE, Capuano IV, Hammerland LG, Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 1995;270:12919-25
   PubMed Web of Science ®Google Scholar
• Ruat M, Snowman AM, Hester LD, Cloned and expressed rat Ca2+-sensing receptor. J Biol Chem 1996;271:5972-5
   PubMedGoogle Scholar
• Ye C, Ho-Pau CL, Kanazirska M, Amyloid-beta proteins activate Ca(2+)-permeable channels through calcium-sensing receptors. J Neurosci Res 1997;47:547-54
   PubMedGoogle Scholar
• Coulombe J, Faure H, Robin B, In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem. Biophys Res Commun 2004;323:1184-90
   PubMed Web of Science ®Google Scholar
• Steddon SJ, Cunningham J. Calcimimetics and calcilytics - fooling the calcium receptor. The Lancet 2005;365:2237-9
   PubMed Web of Science ®Google Scholar
• Trivedi R, Mithal A, Chattopadhyay N. Recent updates on the calcium-sensing receptor as a drug target. Curr Med Chem 2008;15:178-86
   PubMed Web of Science ®Google Scholar
• Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006;109:339-65
   PubMed Web of Science ®Google Scholar
• Hebert SC. Therapeutic use of calcimimetics. Annu Rev Med 2006;57:349-64
   PubMed Web of Science ®Google Scholar
• Chattopadhyay N, Brown EM. Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing. Mol Genet Metab 2006;89:189-202
   PubMedGoogle Scholar
• Wuthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 2007;37:915-22
   PubMedGoogle Scholar
• Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol-Renal 2005;288:F253-264
   PubMed Web of Science ®Google Scholar
• Brown EM, Pollak M, Hebert SC. The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 1998;49:15-29
   PubMed Web of Science ®Google Scholar
• Nemeth EF. The search for calcium receptor antagonists (calcilytics). J Mol Endocrinol 2002;29:15-21
   PubMedGoogle Scholar
• Gowen M, Stroup GB, Dodds RA, Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000;105:1595-604
   PubMed Web of Science ®Google Scholar
• Dempster DW, Cosman F, Parisien M, Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709
   PubMed Web of Science ®Google Scholar
• Reeve J. PTH: a future role in the management of osteoporosis? J Bone Miner Res 1996;11:440-5
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703
   PubMed Web of Science ®Google Scholar
• Petrel C, Kessler A, Maslah F, Modeling and mutagenesis of the binding site of calhex 231, a novel negative allosteric modulator of the extracellular Ca2+ sensing receptor. J Biol Chem 2003;278:49487-94
   PubMedGoogle Scholar
• Petrel C, Kessler A, Dauban P, Positive and negative allosteric modulators of the Ca2+ sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 2004;279:18990-7
   PubMed Web of Science ®Google Scholar
• Hu J, Jiang J, Costanzi S, A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. J Biol Chem 2006;281:21558-65
   PubMedGoogle Scholar
• Huang Y, Zhou Y, Yang W, Identification and dissection of Ca2+ binding sites in the extracellular domain of Ca2+ sensing receptor. J Biol Chem 2007;282:19000-10
   PubMed Web of Science ®Google Scholar
• Miedlich SU, Gama L, Seuwen K, Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J Biol Chem 2004;279:7254-63
   PubMed Web of Science ®Google Scholar
• Ray K, Northup J. Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2+ receptor. J Biol Chem 2002;277:18908-13
   PubMedGoogle Scholar
• Ray K, Tisdale J, Dodd RH, Calindol, a positive allosteric modulator of the human Ca2+ receptor, activates an extracellular ligand-binding domain-deleted rhodopsin-like seven-transmembrane structure in the absence of Ca2+. J Biol Chem 2005;280:37013-20
   PubMedGoogle Scholar
• Nemeth EF, Steffey ME, Hammerland LG, Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-5
   PubMed Web of Science ®Google Scholar
• Fox J, Lowe SH, Petty BA, NPS R-568: a type 2 calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999;290:473-9
   PubMed Web of Science ®Google Scholar
• Fox J, Lowe SH, Conklin RL, Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca2+ receptor in rats. J Pharmacol Exp Ther 1999;290:480-6
   PubMed Web of Science ®Google Scholar
• NPS Pharma, Inc. Calcium receptor-active compounds. WO9612697; 1996
   Google Scholar
• NPS Pharma, Inc. Calcium receptor-active molecules. US6001884; 1999
   Google Scholar
• NPS Pharma, Inc. Calcium receptor-active molecules. US6031003; 2000
   Google Scholar
• Ferry S, Chatel B, Dodd RH, Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cells. Biochem Biophys Res Commun 1997;238:866-73
   PubMedGoogle Scholar
• Silverberg SJ, Bone HG, Marriott TB, Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997;337:1506-10
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Culleton B, Wong G, Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7
   PubMed Web of Science ®Google Scholar
• Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1232-7
   PubMed Web of Science ®Google Scholar
• Moe SM, Cunningham J, Bommer J, Longterm treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005;20:2186-93
   PubMed Web of Science ®Google Scholar
• Shoback DM, Bilezikian JP, Turner SA, The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. Clin Endocrinol Metab 2003;88:5644-9
   Google Scholar
• Peacock M, Bilezikian JP, Klassen PS, Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperthyroidism. J Clin Endocrinol Metab 2005;90:135-41
   PubMed Web of Science ®Google Scholar
• Ortho-McNeil Pharm, Inc. 1,2-Disubstituted cyclopropanes. US6172091; 2001
   Google Scholar
• CNRS (France) Aralkyl-1,2-diamines having calcimimetic activity and preparation mode. WO0134562; 2001
   Google Scholar
• CNRS (France) Novel calcium receptor active molecules and method for preparing same. WO0190069; 2001
   Google Scholar
• Dauban P, Ferry S, Faure H, N1-Arylsulfonyl-N2-(1-aryl)ethyl-3-phenylpropane-1,2-diamines as novel calcimimetics acting on the calcium sensing receptor. Bioorg Med Chem Lett 2000;10:2001-4
   PubMedGoogle Scholar
• Kessler A, Faure H, Petrel C, N2-Benzyl-N1(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg Med Chem Lett 2004;14:3345-9
   PubMed Web of Science ®Google Scholar
• Weston AH, Absi M, Ward DT, Evidence in favor of a calcium-sensing receptor in arterial endothelial cells. Studies with Calindol and Calhex 231. Circ Res 2005;97:391-8
   PubMed Web of Science ®Google Scholar
• Weston AH, Absi M, Harno E, Downregulation of mesenteric artery Ca2+-sensing receptors in a rat model of type 2 diabetes. Br J Pharmacol 2008;154:652-62
   PubMed Web of Science ®Google Scholar
• Wellendorph P, Brauner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene 2004;335:37-46
   PubMed Web of Science ®Google Scholar
• Harno E, Edwards G, Geraghty AR, Evidence for the presence of GPRC6A receptors in rat mesenteric arteries. Cell Calcium 2008;421:210-19
   Google Scholar
• Faure H, Gorojankina T, Rice N, Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor. Cell Calcium 2009;46:323-32
   PubMedGoogle Scholar
• Chen W, Bergsman JB, Wang X, Presynaptic external calcium signalling involves the calcium-sensing receptor in neocortical nerve terminals. PloS One 2010;5:e8563
   Google Scholar
• Tanabe Seiyaku Co. Arylalkylamines and process for production thereof. WO2005115975; 2005
   Google Scholar
• Astellas Pharma, Inc. Pyrrolidine derivative or salt thereof. WO2006123725; 2006
   Google Scholar
• Astellas Pharma, Inc. Piperidine derivatives or salts thereof. WO2008059854; 2008
   Google Scholar
• Leo Pharma A/S. Novel cyclic hydrocarbon compounds for the treatment of diseases. WO2009065406; 2009
   Google Scholar
• Daiichi Sankyo Co. Ltd. Cycloalkylamine derivative. WO2010021351; 2010
   Google Scholar
• Amgen, Inc. Calcium receptor modulating agents. WO03099814; 2003
   Google Scholar
• Amgen, Inc. Calcium receptor modulating agents. WO2009051718; 2009
   Google Scholar
• Amgen, Inc. Calcium receptor modulating agents. WO2008057282; 2008
   Google Scholar
• Leo Pharma A/S. Substituted acetylenic compounds useful for the treatment of diseases. WO2008019690; 2008
   Google Scholar
• Schering Corp. Use of tricyclic amides for the treatment of disorders of calcium homeostasis. WO2004030669; 2004
   Google Scholar
• Aventis Pharma SA. Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use. WO2002059102; 2002
   Google Scholar
• Proskelia SAS. Urea derivatives useful as calcium receptor modulators. WO2007060026; 2007
   Google Scholar
• Proskelia SAS. Derivatives of urea and related diamines, methods for their manufacture and uses therefor. WO2008006625; 2008
   Google Scholar
• Smithkline Beecham Corp. and NPS Pharma, Inc. Calcilytic compounds. WO9845255; 1998 and WO2001008673; 2001
   Google Scholar
• Frolik CA, Black EC, Cain RL, Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003;33:372-9
   PubMed Web of Science ®Google Scholar
• Smithkline Beecham Corp. Calcilytic compounds. WO2002038106; 2002
   Google Scholar
• Smithkline Beecham Corp. Calcilytic compounds. WO2004047751; 2004
   Google Scholar
• Glaxo Group Ltd. Calcilytic compounds. WO2005030749; 2005
   Google Scholar
• Smithkline Beecham Corp. Calcilytic compounds. WO2005077892; 2005
   Google Scholar
• Smithkline Beecham Corp. Calcilytic compounds. WO2008077009; 2008
   Google Scholar
• Pfizer, Inc. 1,1-(Dimethyl-ethylamino)-2-hydroxy-propoxy]-ethyl?-3-methyl-biphenyl-4-carboxylic acid derivatives as calcium receptor antagonists. WO2010103429; 2010
   Google Scholar
• Japan Tobacco, Inc. CaSR antagonist. WO2004094362; 2004
   Google Scholar
• Japan Tobacco, Inc. CaSR antagonist. WO2004106280; 2004
   Google Scholar
• Bristol-Myers Squibb Co. Novel 2-substituted cyclic amines as calcium sensing modulators. WO2004069793; 2004
   Google Scholar
• Bristol-Myers Squibb Co. Substituted piperodines and pyrrolidines as calcium sensing receptor modulators and method. WO2004106295; 2004
   Google Scholar
• Bristol-Myers Squibb Co. Novel thiazolidine compounds as calcium sensing receptor modulators. US2004242602; 2004
   Google Scholar
• Gavai AV, Vaz RJ, Mikkilineni AB, Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists. Bioorg Med Chem Lett 2005;15:5478-82
   PubMedGoogle Scholar
• Smithkline Beecham Corp. Calcilytic compounds. WO2009055631; 2009
   Google Scholar
• Asahi Kasei Pharma Corp. Sulfonamide compound and application thereof. WO2009148052; 2009
   Google Scholar
• CNRS (France). Novel diamines having CaSR modulating activity. WO2002012181; 2002
   Google Scholar
• Kessler A, Faure H, Roussanne MC, N(1)-Arylsulfonyl-N(2)-(1-(1-naphthyl)ethyl)-1,2-diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. ChemBioChem 2004;5:1131-6
   PubMedGoogle Scholar
• Kessler A, Faure H, Petrel C, N1-Benzoyl-N2-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity. J Med Chem 2006;49:5119-28
   PubMedGoogle Scholar
• Novartis AG. Quinazoline derivatives. WO2002102782; 2002
   Google Scholar
• Novartis AG. Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone. WO2004056365; 2004
   Google Scholar
• Novartis AG. Benzoquinazoline derivatives and their use in treating bone disorders. WO2007020046; 2007
   Google Scholar
• Novartis AG. Benzimidazole derivatives. WO2005068433; 2005
   Google Scholar
• Novartis AG. Benzimidazole derivatives. WO2007112913; 2007
   Google Scholar
• Novartis AG. Pharmaceutical compositions comprising a calcilytic agent. WO2008107390; 2008
   Google Scholar
• NPS Pharma, Inc. Quinazolinone compounds as calcilytics. WO2004041755; 2004
   Google Scholar
• Shcherbakova I, Balandrin MF, Fox J, 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg Med Chem Lett 2005;15:1557-60
   PubMed Web of Science ®Google Scholar
• Shcherbakova I, Huang G, Geoffroy OJ, Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg Med Chem Lett 2005;15:2537-40
   PubMedGoogle Scholar
• NPS Pharma, Inc. Chromenone compounds as calcilytics. WO2006042007; 2006
   Google Scholar
• NPS Pharma, Inc. Pyridazinone compounds as calcilytics. WO2007044796; 2007
   Google Scholar
• Smithkline Beecham Corp. Calcilytic compounds. WO2007062370; 2007
   Google Scholar
• Pfizer Products, Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists. WO2008041118; 2008
   Google Scholar
• Takeda Chemical Industries Ltd. Pyrazolopyrimidine derivative and its application. JP2005239611; 2005
   Google Scholar
• Bistol-Myers Squibb Co. Trisubstituted heteroaromatic compounds as calcium receptor modulators. WO2004106296; 2004
   Google Scholar
• Ogata H, Ritz E, Odoni G, Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003;14:959-67
   PubMed Web of Science ®Google Scholar
• Odenwald T, Nakagawa K, Hadtstein C, Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 2006;17:655-62
   PubMed Web of Science ®Google Scholar
• Rybczynska A, Lehmann A, Jurska-Jasko A, Hypertensive effect of calcilytic NPS 2143 administration in rats. J Endocrinol 2006;191:189-95
   PubMedGoogle Scholar
• Smajilovic S, Tfelt-Hansen J. Novel role of the calcium-sensing receptor in blood pressure modulation. Hypertension 2008;52:994-1000
   PubMed Web of Science ®Google Scholar